Podcast: A look at the Amunix drug-conjugation platform

We recently sat down with Volker Schellenberger, Ph.D., President, Amunix, Inc. who will be joining us for the Next Generation Protein Therapeutics Summit. During our conversation  we discussed the Amunix drug-conjugation platform, the therapeutic window of XTEN-based drug conjugates, controlling the chemical structure of XTEN-drug conjugates, the manufacturability of XTEN conjugates and more. Download the podcast to hear the whole conversation.

Dr. Schellenberger will be presenting XTEN: A Protein-Based Polymer that Enables Bioconjugates with Precisely Controlled Chemical Composition on Thursday, June 27 at the Next Generation Protein Therapeutics Summit. If you'd like to know more about his presentation and the rest of the program, download the agenda. If you'd like to join us in Coronado, as a reader of this blog when you register to join us and mention code PTJP13, you'll save 20% off the standard rate. If you have any questions, feel free to email Jennifer Pereira.

Share this article with your social network, just click below to share now!

Share |